Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I): in which the substituents thereof are defined as set forth in the specification.

Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I): in which the substituents thereof are defined as set forth in the specification.

Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I): in which the substituents thereof are defined as set forth in the specification.

Abstract: Analgesic compositions comprise an aminoquinoline together with an opioid, a non-steroidal anti-inflammatory drug (NSAID), a NE/5-HT reuptake inhibitor, or a combination thereof. The aminoquinoline potentiates bioactivity of opioids, NSAIDs and NE/5-HT reuptake inhibitors.

Abstract: Analgesic compositions comprise an aminoquinoline together with an opioid, a non-steroidal anti-inflammatory drug (NSAID), a NE/5-HT reuptake inhibitor, or a combination thereof. The aminoquinoline potentiates bioactivity of opioids, NSAIDs and NE/5-HT reuptake inhibitors.

Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I): in which the substituents thereof are defined as set forth in the specification.

Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I) which is defined in the specification.

Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I) which is defined in the specification.

Abstract: The present invention relates to compositions and methods for identifying and quantifying platelet proteins that relate to various bodily states. The present invention further provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies.

Abstract: A method for the treatment of peripheral neuropathic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from peripheral neuropathic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds. The diphenylureido-dihalokynurenate compounds are shown to be agonists of cannabinoid receptor 1 (CB1) and stimulate CB1 activity.

Abstract: A method for the treatment of chronic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from chronic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds.

Abstract: The present invention relates to compositions and methods for determining whether an individual is predisposed to major depressive disorder and/or to bipolar disorder. In particular, the present invention provides genetic markers useful alone or in combination with other genetic markers for the diagnosis, characterization and treatment of major (unipolar) depression and/or bipolar disorder.

Abstract: The present invention relates to compositions and methods for identifying and quantifying platelet proteins. As certain behaviors and medical conditions alter the quantity of various platelet membrane proteins, the tools of the present invention are suitable for identification of biomarkers of these bodily states. For instance, the present invention provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies.

Abstract: A method for the treatment of chronic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from chronic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds.

Abstract: Compounds, composition and method for ameliorating alcohol or drug dependency withdrawal syndromes and withdrawal-induced brain damage are disclosed. In particular, a series of N-substituted-4-uredo-5,7-dihalo-2-carboxy quinoline compounds are disclosed having combined properties as antagonists of voltage-sensitive sodium channels (VSNaC) and as selective competitive antagonists at the strychnine-intensive glycine site of N-methyl-D-aspartate (NMDA) receptors. The disclosed compounds prevent or reduce the signs and symptoms of neurohyperexcitability and particularly the neurohyperexcitability associated with withdrawal syndrome manifested by patients upon withdrawal from chronic use of dependence inducing agents (e.g. ethanol, barbiturates, opiates etc.).

Abstract: The present invention relates to compositions and methods for regulating neurotransmitter activity in the brains of patients with schizophrenia and addictive disorders. In particular, the present invention provides treatments directed at reducing dopaminergic overactivity.

Abstract: The present invention relates to compositions and methods for determining whether an individual is predisposed to or protected from alcoholism. In particular, the present invention provides genetic markers useful for the diagnosis, characterization, and treatment or prevention of alcohol tolerance, abuse and/or dependence.

Abstract: The present invention relates to compositions and methods for determining whether an individual is predisposed to depression.

Abstract: A method and an assay for ascertaining individuals likely to be predisposed to alcohol abuse is disclosed. The contemplated method ascertains the relative adenylate cyclase and monoamine oxidase activities of blood platelets and includes the steps of isolating platelets from the blood of an individual, assaying the isolated platelets for adenylate cyclase and monoamine oxidase activities, and comparing the observed activities.

Abstract: A therapeutic composition for reducing blood acetaldehyde level in a patient comprises methionine and a physiologically tolerable carrier. Additionally, potassium citrate and Vitamin B6 may be present in the composition.